CHAPTER I

1.1. Background

Acne Vulgaris is one of the most common dermatological condition which dermatologists have to treat. It mainly affect adolescent, though may present at any age. Although acne is not a life threatening condition, it has a substantial psychological impact, leaving both physical and emotional scars on those who suffer. The principal hallmarks of acne include follicular hyperproliferation and plugging, extensive formation of sebum, activity of Propionibacterium acnes, inflammation and hormones.¹In recent years, due to better understanding of the pathogenesis of acne, new therapeutic modalities and combinations have been designed. In topical agents; benzoyl peroxide, antibiotics, retinoids, etc are the main therapy for acne vulgaris or they can be given in combinations. While systemic therapy includes isotretinoin, oral antibiotics such as macrolides and tetracyclines, hormone-based therapies can be separated into two broad categories: androgen synthesis inhibitors and androgen receptor antagonists. Estrogen and progesterone derivatives, are generally considered androgen synthesis inhibitors. Commonly known androgen receptor antagonists include agents such as spironolactone, flutamide, cyproterone acetate, and progestins.² Which therapy to use is depend on the need of patients and it has to be selected. Specially in hormone therapy we must be very careful cause the side effect of hormone therapy such as cardiovascular risk and cancer risk must be consider. To avoid or to minimize the side effect of hormone therapy and to get better

treatment for acne vulgaris, we would like to know the effectiveness of isoflavone for acne vulgaris therapy.

According to the Global Burden of Disease (GBD) study, acne vulgaris affects about 85% of young adults aged 12–25 years.³ Acne consistently represents the top three most prevalent skin conditions in the general population, as found in large studies with in the UK, France, and the USA. Similar numbers are reported for young adults in various countries through out the world. Epidemiological studies have demonstrated a higher incidence of acne vulgaris in different ethnicities of color in samples collected from the population aged 10–70 years. Data collected from 1990 to 2010 GBD was analyzed. Exhibits a general upward trajectory for all regions except Sub-Saharan Africa, with a clear separation in both prevalence and rate of incline between traditionally more wealthy regions (Western Europe, high-income Asia Pacific, US, and Canada) and traditionally poorer regions (Sub-Saharan Africa, Oceania, Latin America, and Caribbean). Similar patterns are seen for incidence and rate of incline in the comparison of developing versus developed nations.

Many research had been done finding the benefit of isoflavone. Isoflavone have been proven to have benefit for cardiovaskular health by affecting the vascular tone through a combination of mechanisms including endothelialdependent and endothelial independent vasodilator systems and inhibition of constrictor mechanisms. These processes involve both classical genomic as well as non-genomic mechanisms of action. Activation of nuclear ERs by isoflavones was found to increase expression of endothelial NO-synthase (eNOS), reduce oxidative stress and increase NO bioavailability.⁴ In postmenopausal women, consumption of isoflavones was found to be associated with reduction of breast cancer incidence, mammary gland density, and proliferation ability of mammary gland cells. These effects have been associated with the ability of isoflavones to increase serum SHBG concentration, there by reducing the bioavailability of sexual hormones in hormone-dependent tissues.⁴ Moreover, in peripheral tissues, isoflavones inhibit enzymes involved in the processes of cell proliferation (e.g. tyrosine kinase) and reduce estradiol availability through the inhibitory effect on aromatase P450. Similarly to estradiol, isoflavones pass through the blood-brain barrier. Consumption of large amounts of soybeans increased the concentration of isoflavones in basal parts of the hypothalamus, the hippocampus, the cerebellum, and the frontal cortex. This corresponds well with regional expression of $ER\beta$, which bind isoflavones. In contrast to peripheral tissues, the activity of aromatase P450 in the brain seems to be unaffected by dietary isoflavones. Surprisingly, decreased activity of 5a-reductase in the hypothalamus and amygdala has been reported at low, but not at high isoflavones intake.

Pilosebaceous units possess all the steroid metabolizing enzymes needed to convert dehydroepiandrosterone to the most potent androgen, dihydrotestosterone (DHT), including 3b -hydroxsteroid dehydrogenase , and 5a -reductase (5a - R).¹Soybean isoflavone has active components, they are genistein, daidzein and glycitein.⁴ The role of soybean isoflavone in androgen metabolism is to restrict the enzyme 3B-hydroxysteroid dehydrogenase (3B-HSD), 17B-hydroxysteroid dehydrogenase (17B-HSD) and the enzyme 5a-reductase.⁴In the previous research

about the benefit of isoflavone has been found that with the dose of 160 mg of isoflavone will reduce the amount of sebum production, acne vulgaris lessions and the level of DHT.⁵ In this continues research we would like to know which is the best way of isoflavone 160 mg will give the best result in therapy of acne vulgaris. The association between consumption of soybean isoflavone and acne vulgaris is not known yet, so a study on the influence of soybean isoflavone supplementation on women with acne vulgaris by investigating androgen hormone that has association with the amount of acne vulgaris lesion, then formulate the problem of whether oral or topical soybean isoflavone has influence on amount of sebum and DHT hormone in acne vulgaris.

1.2. Problem of Research

Will oral or topical isoflavone therapy decrease the amount of sebum, decrease the activity of DHT reseptor and will isoflavone change the histology of sebacea gland.

1.3. Purpose of the Research

1.3.1. General Purpose

In this research we would like to know the effectiveness different of isoflavone oral or topical for acne vulgaris therapy by measuring the amount of sebum, the activity of DHT reseptor and histology of sebacea gland.

1.3.2. Specific Purpose

- To investigate what is the effect of oral or topical of 16 mg isoflavones therapy to decrease the amout of sebum
- 2. To investigate what is the effect of oral or topical of 16 mg isoflavones therapy to decrease the activity of dihydrotestosterone (DHT) reseptor
- 3. To investigate what is the effect of oral or topical of 16 mg isoflavones therapy that can change the histology of sebacea gland

1.4. Research Originality

This research has not been done before, in this research we try to find out the effectiveness differences between oral or topical soybean isoflavone for acne therapy and comparing with the gold standart therapy that has been used until now.

Name,Year	Title	Metode	Result
Puguh	Advantage of Soybean	The study design is	Supplementatio
Riyanto,Prase	isoflavone as	true experimental	n with 160
tyowati	antiandrogen on acne	clinical study using	mg/day of
Subchan and	vulgaris	randomized pretest-	soybean
Rosa Lelyana		posttest control	isoflavone can
2015		group design. This	reduce total
		study used dosage of	AV lesion as a
		160 mgs soybean	result of
		isoflavone for	decreased DHT

0 mg for placebo group for 12 weeks,PuguhSoy IsoflavonesRandomized pre- and post-test controlThe treatmentRiyanto andReduce Toll-likeand post-test controlof 160 mg/dayRosaReceptor-2 Levels indesign, with 40soy isoflavonesLelyana, 2017Acne Vulgaris.women, randomizedfor 12 weeks in into 2 groups:women withJacebo andsuffered AVreatment. This studylesions has inad one for 12soy isoflavonesLelyana, 2017Keney Levelsweeks.significantreduction in total AVPuguhEffect of SoyIn this study was aTreatment with soy isoflavonesPuguhEffect of SoyIn this study was aTreatment with soy isoflavonesRiyanto 2017Isoflavones on the umprovement of Acecandomized160 mg / dayRiyanto 2017Keducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdesree of AV			treatment group and	level.
group for 12 weeks,PuguhSoy IsoflavonesRandomized pre- and post-test controlThe treatmentRiyanto andReduce Toll-likeand post-test controlof 160 mg/dayRosaReceptor-2 Levels indesign, with 40soy isoflavonesLelyana, 2017Acne Vulgaris.women, randomizedfor 12 weeks in into 2 groups:women withplacebo andsuffered AVtreatment. This studylesions has ins done for 12significantreduction inreduction in total AV lesionsreduction in total AV lesionsPuguhEffect of SoyIn this study was aTreatment with soy isoflavonesRiyanto 2017Isoflavones on the umprovement of Acneclinical study withsoy isoflavonesRugaris Severity by Necrosis Factor-acontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve the			0 mg for placebo	
PuguhSoy IsoflavonesRandomized pre- and post-test controlThe treatmentRiyanto andReduce Toll-likeand post-test controlof 160 mg/dayRosaReceptor-2 Levels indesign, with 40soy isoflavonesLelyana, 2017Acne Vulgaris.women, randomizedfor 12 weeks in into 2 groups:women withplacebo andsuffered AVtreatment. This studylesions has has done for 12proved aweeks.significantreduction in total AV lesionscause of the reduction in total AV lesionsPuguhEffect of SoyIn this study was aTreatment with soy isoflavonesRiyanto 2017Isoflavones on the Improvement of AcneIn this study with randomizedsoy isoflavonesRegultEffect of SoyIn this study with soy isoflavonesfor 12 weeksRiyanto 2017Isoflavones on the Improvement of Acne Reducing TumorIn this study mata pretest-posttestfor 12 weeksRegultEffect of SoyIn this study with soy isoflavonesfor 12 weeks			group for 12 weeks,	
Riyanto andReduce Toll-likeand post-test controlof 160 mg/dayRosaReceptor-2 Levels indesign, with 40soy isoflavonesLelyana, 2017Acne Vulgaris.women, randomizedfor 12 weeks inIclyana, 2017Face of andsuffered AVsuffered AVIcly andplacebo andsuffered AVIcly andreatment. This studylesions hasIcly andKerosis Factor-areaduction inIcly andIcly andreduction inIcly andIcly andreduction inIcly andIcly and	Puguh	Soy Isoflavones	Randomized pre-	The treatment
RosaReceptor-2 Levels indesign, with 40soy isoflavonesLelyana, 2017Acne Vulgaris.women, randomizedfor 12 weeks ininto 2 groups:into 2 groups:women withplacebo andsuffered AVreatment. This studylesions hashas done for 12proved aweeks.significantreduction intotal AV lesionscause of thereduction intotal AV lesionscause of thereduction inTLR-2 levels.PuguhEffect of SoyIn this study was aRiyanto 2017Isoflavones on thecaincial study withimprovement of Acerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksNecrosis Factor-adesign. 40 patientsdegree of AV	Riyanto and	Reduce Toll-like	and post-test control	of 160 mg/day
Lelyana, 2017Acne Vulgaris.women, randomizedfor 12 weeks ininto 2 groups:women withplacebo andsuffered AVtreatment. This studylesions hashas done for 12proved aweeks.significantreduction intotal AV lesionscause of thereduction intotal AV lesionscause of thePuguhEffect of SoyIn this study was aRiyanto 2017Isoflavones on theclinical study withImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksNecrosis Factor-adesign. 40 patientsdegree of AV	Rosa	Receptor-2 Levels in	design, with 40	soy isoflavones
into 2 groups: women with placebo and suffered AV treatment. This study has done for 12 proved a weeks. ignificant idual AV lesions cause of the reduction in total AV lesions cause of the reduction in TLR-2 levels. Puguh Effect of Soy In this study was a Fuguh Effect of Soy In this study was a Improvement of Acne improvement of Acne Auguaris Severity by controled group for 12 weeks cau improve the can impro	Lelyana, 2017	Acne Vulgaris.	women, randomized	for 12 weeks in
placebo andsuffered AVtreatment. This studylesions hashas done for 12proved abas done for 12veeks.significantreduction intotal AV lesionscause of thetotal AV lesionsreduction intotal AV lesionsreduction intotal AV lesionsreduction intreatment of Acmecause of thekiyanto 2017Isoflavones on theclinical study was aImprovement of Acmerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksNecrosis Factor-adesign.40 patientsdegree of AV			into 2 groups:	women with
reatment. This studylesions hashas done for 12proved aweeks.significantreduction inreduction intotal AV lesionscause of thereduction inreduction intotal AV lesionscause of thereduction inTLR-2 levels.PuguhEffect of SoyIn this study was aRiyanto 2017Isoflavones on theclinical study withImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksNecrosis Factor-adesign. 40 patientsdegree of AV			placebo and	suffered AV
has done for 12 proved a weeks. significant reduction in total AV lesions cause of the reduction in TLR-2 levels. Puguh Effect of Soy In this study was a Riyanto 2017 Isoflavones on the Improvement of Acne Improvement of Acne Acne Reducing Tumor Necrosis Factor-a Marce Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne Acne			treatment. This study	lesions has
weeks.significantreduction inreduction intotal AV lesionscause of thecause of thereduction inTLR-2 levels.TLR-2 levels.PuguhEffect of SoyIn this study was aTreatment withRiyanto 2017Isoflavones on theclinical study withsoy isoflavonesImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve the			has done for 12	proved a
reduction intotal AV lesionscause of thereduction inreduction inTLR-2 levels.PuguhEffect of SoyIn this study was aTreatment withRiyanto 2017Isoflavones on theclinical study withImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV			weeks.	significant
total AV lesionscause of thereduction inTLR-2 levels.PuguhEffect of SoyIn this study was aTreatment withRiyanto 2017Isoflavones on theclinical study withsoy isoflavonesImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupReducing Tumorpretest-posttestNecrosis Factor-adesign. 40 patients				reduction in
cause of the reduction in TLR-2 levels.PuguhEffect of SoyIn this study was aTreatment withRiyanto 2017Isoflavones on the Improvement of Acneclinical study with randomizedsoy isoflavonesMugaris Severity by Reducing Tumorcontroled groupfor 12 weeks can improve the degree of AV				total AV lesions
PuguhEffect of SoyIn this study was aTreatment withRiyanto 2017Isoflavones on theclinical study withsoy isoflavonesImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV				cause of the
PuguhEffect of SoyIn this study was aTreatment withRiyanto 2017Isoflavones on theclinical study withsoy isoflavonesImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV				reduction in
PuguhEffect of SoyIn this study was aTreatment withRiyanto 2017Isoflavones on theclinical study withsoy isoflavonesImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV				TLR-2 levels.
Riyanto 2017Isoflavones on theclinical study withsoy isoflavonesImprovement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV	Puguh	Effect of Soy	In this study was a	Treatment with
Improvement of Acnerandomized160 mg / dayVulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV	Riyanto 2017	Isoflavones on the	clinical study with	soy isoflavones
Vulgaris Severity bycontroled groupfor 12 weeksReducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV		Improvement of Acne	randomized	160 mg / day
Reducing Tumorpretest-posttestcan improve theNecrosis Factor-adesign. 40 patientsdegree of AV		Vulgaris Severity by	controled group	for 12 weeks
Necrosis Factor-a design, 40 patients degree of AV		Reducing Tumor	pretest-posttest	can improve the
		Necrosis Factor-a	design. 40 patients	degree of AV

	Levels.	were randomized	severity as a
		into 2 groups: soy	result of a
		isoflavones 160	decrease in
		mg/day and control.	TNF-α.
		The duration of this	
		study was 12 weeks	
Koltun et al.,	Efficacy and safety of	Randomized double-	COC group had
2008.	3 mg DRSP	blind placebo	4.31 odds of
	(yasmin)/20 mcg EE	controlled trial.	clear/almost
	oral contraceptive		clear skin as
	administered in 24/4		assessed by
	regimen in the		investigators
	treatment of acne		after six 28-day
	vulgaris: A		cycles
	randomized, double-		compared with
	blind, placebo-		placebo (p =
	controlled trial.		.001).
NIU	Efficacy Observation	To observe the	The
Ben,WANG	of Moxa Flavone on	influences of 60,30	experiments
Ai-	Experimental Acne.	mg•kg-1 moxa	show that moxa
xia,LIANG		flavone on models of	flavone can cure
Ning,GAO		experimental rabbit	acne through
Jun 2012.		ear keratinization,the	the

		influences of	experimental
		60,30,15 mg • kg-1	keratinization,th
		moxa flavone on the	e blood
		models of the rat	circulation
		voix pedis	activating, stasis
		engorgement and	eliminating,antii
		rats blood stasis	nflammatory
		syndrome.	action,immunos
			uppression and
			androgen
			depreciation.
Palli et al.,	: A single-center,	Randomized double-	COC group
2013.	randomized double-	blind parallel-group	experienced
	blind, parallel-group	study.	significantly
	study to examine the		greater
	safety and efficacy of		reductions in
	3 mg DRSP/0.02 mg		noninflammator
	EE compared with		y and total acne
	placebo in the		count by week
	treatment of moderate		24 compared
	truncal acne vulgaris		with placebo (p
			= .02).

1.5. Benefit Of The Research

1.5.1. Scientific Benefit

From this research we can find out which is the best way of isoflavone (oral or topical) for acne vulgaris therapy. Isoflavone can reduce the amount of sebum, decrease the DHT reseptor activity and change the histology of sebacea gland.

1.5.2. Practical Benefit

The result of this research will give us knowledge about the benefit of oral and topical isoflavone in acne vulgaris therapy and what is the best way to be use. Isoflavone maybe one of the alternative therapy for acne vulgaris. This will help the community to seak therapy and to prevent acne vulgaris. And we can reduce or prevent the side effect of hormonal therapy in acne.